BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12824030)

  • 1. 1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.
    Ukita T; Nakamura Y; Kubo A; Yamamoto Y; Moritani Y; Saruta K; Higashijima T; Kotera J; Fujishige K; Takagi M; Kikkawa K; Omori K
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2341-5. PubMed ID: 12824030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.
    Ukita T; Nakamura Y; Kubo A; Yamamoto Y; Moritani Y; Saruta K; Higashijima T; Kotera J; Takagi M; Kikkawa K; Omori K
    J Med Chem; 2001 Jun; 44(13):2204-18. PubMed ID: 11405657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors.
    Wang Y; Chackalamannil S; Hu Z; Boyle CD; Lankin CM; Xia Y; Xu R; Asberom T; Pissarnitski D; Stamford AW; Greenlee WJ; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3149-52. PubMed ID: 12372521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of novel, potent and selective PDE5 inhibitors.
    Bi Y; Stoy P; Adam L; He B; Krupinski J; Normandin D; Pongrac R; Seliger L; Watson A; Macor JE
    Bioorg Med Chem Lett; 2001 Sep; 11(18):2461-4. PubMed ID: 11549447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
    Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
    Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FR226807: a potent and selective phosphodiesterase type 5 inhibitor.
    Hosogai N; Hamada K; Tomita M; Nagashima A; Takahashi T; Sekizawa T; Mizutani T; Urano Y; Kuroda A; Sawada K; Ozaki T; Seki J; Goto T
    Eur J Pharmacol; 2001 Oct; 428(2):295-302. PubMed ID: 11675048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rabbit corpus cavernosum smooth muscle shows a different phosphodiesterase profile than human corpus cavernosum.
    Qiu Y; Kraft P; Lombardi E; Clancy J
    J Urol; 2000 Sep; 164(3 Pt 1):882-6. PubMed ID: 10953172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
    Wallis RM; Corbin JD; Francis SH; Ellis P
    Am J Cardiol; 1999 Mar; 83(5A):3C-12C. PubMed ID: 10078537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide.
    Kalsi JS; Kell PD; Cellek S; Ralph DJ
    Int J Impot Res; 2004 Apr; 16(2):195-200. PubMed ID: 14961060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.
    Ballard SA; Gingell CJ; Tang K; Turner LA; Price ME; Naylor AM
    J Urol; 1998 Jun; 159(6):2164-71. PubMed ID: 9598563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5'-sulfonamide moiety of a phenyl ring.
    Kim DK; Lee JY; Lee N; Ryu DH; Kim JS; Lee S; Choi JY; Ryu JH; Kim NH; Im GJ; Choi WS; Kim TK
    Bioorg Med Chem; 2001 Nov; 9(11):3013-21. PubMed ID: 11597484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
    Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of human, dog and rabbit corpus cavernosum type 5 phosphodiesterases.
    Wang P; Wu P; Myers JG; Stamford A; Egan RW; Billah MM
    Life Sci; 2001 Mar; 68(17):1977-87. PubMed ID: 11388700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and phosphodiesterase 5 inhibitory activity of new sildenafil analogues containing a phosphonate group in the 5(')-sulfonamide moiety of phenyl ring.
    Kim DK; Young Lee J; Park HJ; Minh Thai K
    Bioorg Med Chem Lett; 2004 May; 14(9):2099-103. PubMed ID: 15080987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
    Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
    Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
    Turko IV; Ballard SA; Francis SH; Corbin JD
    Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5.
    Wallis RM
    Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():22P-26P. PubMed ID: 10629850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.
    Rotella DP; Sun Z; Zhu Y; Krupinski J; Pongrac R; Seliger L; Normandin D; Macor JE
    J Med Chem; 2000 Apr; 43(7):1257-63. PubMed ID: 10753463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum.
    Takagi M; Mochida H; Noto T; Yano K; Inoue H; Ikeo T; Kikkawa K
    Eur J Pharmacol; 2001 Jan; 411(1-2):161-168. PubMed ID: 11137871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor.
    Mochida H; Takagi M; Inoue H; Noto T; Yano K; Fujishige K; Sasaki T; Yuasa K; Kotera J; Omori K; Kikkawa K
    Eur J Pharmacol; 2002 Dec; 456(1-3):91-8. PubMed ID: 12450574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.